Major bleeding was low overall, but the findings align with other large datasets showing greater risk with rivaroxaban.

Rates of major bleeding and intracranial hemorrhage are similar for apixaban and dabigatran versus aspirin, while rates are ...

Novartis is acquiring Anthos Therapeutics for up to $3.08 billion, adding abelacimab, a late-stage anticoagulant, to its ...

Experts discuss PPI use for GI protection in patients on antithrombotics, highlighting risk factors, dosing, drug ...

Novartis has agreed to acquire Boston-based clinical-stage biopharmaceutical company Anthos Therapeutics for an upfront ...

Novartis (NVS) announced that it has entered into an agreement to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, ...

Novartis said it has agreed to acquire U.S. privately held, clinical-stage biopharmaceutical company Anthos Therapeutics for up to $3.08 billion to boost its cardiovascular pipeline.

A systematic review and meta-analysis estimating the differences in bleeding risks between therapeutic-dose non-vitamin K oral anticoagulants (NOACs) and single antiplatelet therapy (aspirin) found ...

The benefit of direct oral anticoagulants on stroke risk in patients with prior intracerebral hemorrhage and atrial ...

Some clinicians prefer aspirin when balancing bleeding risk with the indication for an anticoagulant, Barnes said, reasoning ...

LOS ANGELES -- In the PRESTIGE-AF trial, survivors of intracerebral hemorrhage (ICH) had good protection against future ischemic events using direct oral anticoagulants (DOACs) -- though, as feared, ...

A single-center study suggests the surgery is safe and effective even when tumors are large or located in high-risk areas.